Answers are grounded in this paper and cite their sources.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master transcription factor that orchestrates antioxidant, detoxification, and anti-inflammatory responses, playing a pivotal role in maintaining homeostasis within the female reproductive system. Under basal conditions, Keap1 functions as a substrate adaptor for the CUL3-RBX1 ubiquitin ligase complex and promotes continuous ubiquitination and proteasomal degradation of Nrf2. Oxidative or electrophilic modification of Keap1 cysteine residues impairs this process, allowing newly synthesized Nrf2 to accumulate, translocate to the nucleus, heterodimerize with small Maf proteins, and regulate ARE-containing genes, including HO-1, NQO1, GCLC/GCLM, GSTs, SLC7A11, and TrxR. Accumulating preclinical evidence—derived predominantly from oxidative-challenge, aging, toxicant, and disease models—suggests that Nrf2 signaling can modify oocyte spindle stability, granulosa-cell survival and steroidogenic gene expression, ovarian responses to aging or toxicants, and preimplantation embryo development under adverse conditions. Evidence for a direct role of Nrf2 in basal reproductive physiology, particularly in regulation of the hypothalamic-pituitary-ovarian axis, remains limited. Because these findings were largely obtained under experimentally elevated oxidative stress, whether Nrf2 exerts reproductive-specific actions beyond its universal cytoprotective function remains to be established. In experimental models, Nrf2 deficiency is associated with compromised oocyte quality, accelerated stress-induced follicular atresia, and impaired embryonic development. In preclinical models, targeted activation of the Nrf2 pathway shows therapeutic potential in PMOS, EMs, and GDM; however, these remain largely non-causal preclinical findings, and cell-specific genetic studies together with clinical trials are required before Nrf2 can be considered a safe therapeutic target. Importantly, however, constitutive Nrf2 activation resulting from Keap1 mutations or prolonged pharmacological over-stimulation may promote the progression of gynecological malignancies and contribute to chemoresistance. This dual role underscores the necessity for precision-based Nrf2-targeted interventions guided by rigorous tumor risk stratification. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: